clinical endpoint raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-23 and is reviewed periodically as new material appears.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | 28 residues; not a small-molecule compound |
| Molecular mass | About 3,106 Da | Monoisotopic mass of the unmodified chain |
| N-terminal group | Acetylated serine | Present in both native and synthetic forms |
| Secondary structure | Disulfide-constrained loop | One bridge between two cysteine residues |
| Typical source | Solid-phase synthesis | Early isolates came from bovine thymus extracts |
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
==== Proteins ==== Mashua is a food item known for its exceptional nutritional properties. The protein content of the dry weight was reported to be about 6.9–15.7%. It has a remarkable protein profile with a considerable abundance of essential amino acids in an ideal ratio, providing a high biological value. The essential amino acids leucine, isoleucine, and valine are branched-chain amino acids (BCAA), which are essential in muscle metabolism. The amount of free amino acids ranges from 2.763 to 6.826 mg/g dry matter. Variations occur depending on the region of cultivation and the specific mashua genotype.
The two substrates of this enzyme are epipregnanolone and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are 5β-dihydroprogesterone, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 3beta-hydroxy-5beta-steroid:NADP+ 3-oxidoreductase. Other names in common use include 3beta-hydroxysteroid 5beta-oxidoreductase, and 3beta-hydroxysteroid 5beta-progesterone oxidoreductase.
==== Conventional recycle processes ==== In early "straight-through" urea plants, reactant recovery (the first step in recycling) was done by letting down the system pressure to atmospheric to let the carbamate decompose back to ammonia and carbon dioxide. Originally, because it was not economic to recompress the ammonia and carbon dioxide for recycle, the ammonia at least would be used for the manufacture of other products such as ammonium nitrate or ammonium sulfate, and the carbon dioxide was usually wasted. Later process schemes made recycling unused ammonia and carbon dioxide practical. This was accomplished by the "total recycle process", developed in the 1940s to 1960s and now called the conventional recycle process. It proceeds by depressurizing the reaction solution in stages (first to 1.8–2.5 MPa (260–360 psi) and then to 0.2–0.5 MPa (29–73 psi)) and passing it at each stage through a steam-heated carbamate decomposer, then recombining the resulting carbon dioxide and ammonia in a falling-film carbamate condenser and pumping the carbamate solution back into the urea reaction vessel.
=== Affinity-based proteome analysis tools === The definition of TDP includes a requirement to identify the "protein", either as a distinct proteoform or ORF product. While this is most typically achieved using a mass spectrometer to fragment ions, from either intact proteoforms or peptides of resolved proteoforms, it is also possible to identify and quantify canonical "proteins" using affinity-based reagents, such as O-link and SomaScan which use antibodies or aptamers, respectively. The generic term "protein" is used here because it is unclear whether these reagents identify certain proteoforms or a variety of proteoforms from the same ORF product. These methods thus produce similar, yet different, information relative to each other and to proteogenomic BUP approaches using LC/MS/MS. Because of the claimed (i) "depth" of these assays in terms of identifying canonical protein sequences; and (ii) apparent ability to quantify changes in the abundance of those proteins in samples that can be problematic for other proteomics technologies (e.g. plasma and serum), these technologies have become popular in studies having enormous sample numbers that are impossible to directly address by other proteomics technologies. However, the substantial lack of correlation between these technologies, as well as with other established proteomics technologies, needs to be addressed, along with fully characterizing the exact proteoforms that these reagents are identifying. This will thus also require transparent verification of the quality and selectivity of any antibodies and aptamers used.
A 2024 systematic review of human and animal observational studies concluded that MNPs are "suspected" to be harmful to human reproductive, respiratory, and digestive health. The World Health Organization has acknowledged growing concerns, but note that standardized measurement methods and risks have not been established, calling for further research and improved management of plastic throughout its life-cycle.
Sources: en.wikipedia.org
==== Drug delivery ==== Emerging methods of drug delivery involving nanotechnological methods can be useful by improving bodily response, specific targeting, and non-toxic metabolism. Many nanotechnological methods and materials can be functionalized for drug delivery. Ideal materials employ a controlled-activation nanomaterial to carry a drug cargo into the body. Mesoporous silica nanoparticles (MSN) have increased in research popularity due to their large surface area and flexibility for various individual modifications while maintaining high-resolution performance under imaging techniques. Activation methods greatly vary across nanoscale drug delivery molecules, but the most commonly used activation method uses specific wavelengths of light to release the cargo. Nanovalve-controlled cargo release uses low-intensity light and plasmonic heating to release the cargo in a variation of MSN containing gold molecules. The two-photon activated photo-transducer (2-NPT) uses near infrared wavelengths of light to induce the breaking of a disulfide bond to release the cargo. Recently, nanodiamonds have demonstrated potential in drug delivery due to non-toxicity, spontaneous absorption through the skin, and the ability to enter the blood–brain barrier. The unique structure of carbon nanotubes also gives rise to many innovative inventions of new medical methods. As more medicine is made at the nano level to revolutionize the ways for human to detect and treat diseases, carbon nanotubes become a stronger candidate in new detection methods and therapeutic strategies.
S. divinorum (0.89 mg/g to 3.70 mg/g). S. recognita (212.9 μg/g). S. cryptantha (51.5 μg/g). S. glutinosa (38.9 μg/g). Salvinorin B has been detected in S. potentillifolia and S. adenocaulon, however these species do not contain a measureable amount of salvinorin A.
== Known members == For a key to the single-letter sequences, see Amino acid § Table of standard amino acid abbreviations and properties. All peptides sequences are assumed to start with NH2- and end with -COOH, unless otherwise stated.
Bariatric surgery, particularly Roux-en-Y gastric bypass and sleeve gastrectomy, have demonstrated effectiveness in promoting weight loss and improving diabetes outcomes among severely obese individuals. A 2021 Evidence Update for Clinicians found that Roux-en-Y gastric bypass patients experienced slightly better weight loss and diabetes control outcomes than sleeve gastrectomy patients, though with a higher risk for rehospitalization and need for additional surgeries. In one study there was an unexplained increase in deaths from accidents and suicide, but this did not outweigh the benefit in terms of disease prevention. When the two main techniques are compared, gastric bypass procedures are found to lead to 30% more weight loss than banding procedures one year after surgery. For obese individuals with non-alcoholic fatty liver disease (NAFLD), bariatric surgery improves or cures the liver. A preoperative diet such as low-calorie diets or very-low-calorie diet, is usually recommended to reduce liver volume by 16-20%, and preoperative weight loss is the only factor associated with postoperative weight loss. Preoperative weight loss can reduce operative time and hospital stay. although there is insufficient evidence whether preoperative weight loss may be beneficial to reduce long-term morbidity or complications. Weight loss and decreases in liver size may be independent from the amount of calorie restriction. Ileojejunal bypass, in which the digestive tract is rerouted to bypass the small intestine, was an experimental surgery designed as a remedy for morbid obesity.
Sources: en.wikipedia.org
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.